

Instructions for Authors 2017

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. Anticancer Res 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: Receptors for Reproductive Hormones (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergery’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iilar-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2017 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.
- The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iar-anticancer.org; Iiar websites: www.iar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles

Effectiveness of Analogues of the GS-Nitroxide, JP4-039, as Total Body Radiation Mitigators. M.W. EPPERLY, J.R. SACHER, T. KRAINZ, X. ZHANG, P. WIPF, M. LIANG, R. FISHER, S. LI, H. WANG, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Wound Healing is Delayed in the ZDSD Rat. M.A. SUCKOW, T.A. GOBBETT, R.G. PETERSON (*St. Paul, MN; Indianapolis, IN, USA*)

Active and Passive Immunization Against *Staphylococcus aureus* Periprosthetic Osteomyelitis in Rats. N.H.SØE, N.V. JENSEN, A.L. JENSEN, J. KOCH, S.S. POULSEN, G.B. PIER, H.K. JOHANSEN (*Copenhagen; Ballerup; Hørsholm, Denmark; Boston, MA, USA*)

Effective Mediastinal Lymphadenectomy for Esophageal Cancer Using Slender Tracheal Forceps in Prone Position Thoracoscopic Esophagectomy. M. NAKAJIMA, M. TAKAHASHI, Y. DOMEKI, H. SATOMURA, H. MUROI, M. KIKUCHI, H. OGATA, S. YAMAGUCHI, K. SASAKI, M. SAKAI, M. SOHDA, T. MIYAZAKI, H. KUWANO, H. KATO (*Mibu; Maebashi, Japan*)

A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. P.B. CAFFREY, G.D. FRENKEL, K.L. MCANDREW, K. MARKS (*California; Pittsburgh, PA; Newark, NJ, USA*)

Applicability of Commercially Available ELISA Kits for the Quantification of Faecal Immunoreactive Corticosterone Metabolites in Mice. K.S.P. ABELSON, O. KALLIOKOSKI, A.C. TEILMANN, J. HAU (*Copenhagen, Denmark*)

Gene Expression Analysis of Cultured Rat-Endothelial Cells after Nd: YAG Laser Irradiation by Affymetrix GeneChip Array. Y. MASUDA, S. YOKOSES, H. SAKAGAMI (*Saitama, Japan*)

Polymorphism in Murine mtATP8 Gene Correlates with Decreased Reactive Oxygen Species in Aging Hematopoietic Cells. C. ROOLF, C. KRETZSCHMAR, K. TIMMER, A. SEKORA, G. KNÜBEL, H.M. ESCOBAR, G. FUELLEN, S.M. IBRAHIM, M. TIEDGE, S. BALTRUSCH, S. MÜLLER, R. KÖHLING, C. JUNGHANSS (*Rostock, Germany*)

Induction of TGF-β by Irradiation or Chemotherapy in Fanconi Anemia (FA) Mouse Bone Marrow is Modulated by Small Molecule Radiation Mitigators JP4-039 and MMS350. M.W. EPPERLY, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, D. SHIELDS, H. WANG, P. WIPF, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Prognostic Impact of a Nutritional Index Including Muscle Volume in Stage 4 Colorectal Cancer. T. NAGATA, Y. NAKASE, K. NAKAMURA, A. SOUGAWA, S. MOCHIDUKI, S. KITAI, S. INABA (*Nara, Japan*)

Cell Pleomorphism and Cytoskeleton Disorganization in Human Liver Cancer. C.-C. CHENG, Y.-C.C. LAI, Y.-S. LAI, W.-T. CHAO, Y.-H. TSENG, Y.-H. HSU, Y.-Y. CHEN, Y.-H. LIU (*Changhua; Taichung; Kaohsiung; Hualien, Taiwan, ROC*)

The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model. M.L. HENRIKSEN, A. TEISNER, J. KJELDSEN, O. KALLIOKOSKI, J. HAU, S. WERNER, K. HANSEN (*Odense; Copenhagen, Denmark*)

Palliative Radiotherapy in Cancer Patients with Increased Serum C-reactive Protein Level. C. NIEDER, B. MANNSÅKER, A. DALHAUG, A. PAWINSKI, E. HAUKLAND (*Tromsø; Bodø, Norway*)

Simvastatin Inhibits Epithelial-to-Mesenchymal Transition Induction of HO-1 in Cultured Renal Proximal Tubule Cells. J.S. CLARK, A.J. CARTER, M. DIXIT, I. ARANY (*Jackson, MS, USA*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

CANCER GENOMICS & PROTEOMICS

www.cgpiiarjournals.org

Print ISSN (2004-2012): 1109-6535
Online ISSN: 1790-6245
VOL. 1 (2004) - VOL. 9 (2012) (print and online)
From VOL. 10 (2013) online – only and open access



International Online Open Access Journal

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research (IIAR)** and is available online with **Stanford University HighWire Press**. The IIAR is a member of UICC. For more information please visit our website www.cgpiiarjournals.org.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iilar-anticancer.org; IIAR websites: www.iilar-anticancer.org and www.iilarjournals.org

A Selection of Recent Articles

Differential Expression of Wisp1 (Ccn4) and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells. M.S. CHAHAL, H.T. KU, Z. ZHANG, C.M. LEGASPI, A. LUO, M.M. HOPKINS, K.E. MEIER (*Spokane, WA; Duarte, CA, USA*)

Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. M. MEDINGER, C. LENGERKE, J. PASSWEG (*Basel, Switzerland*)

EPHA7 and EPHA10 Physically Interact and Differentially Co-localize in Normal Breast and Breast Carcinoma Cell Lines, and the Co-localization Pattern Is Altered in EPHB6 Expressing MDA-MB-231 Cells. C. JOHNSON, B. SEGOVIA, R.P. KANDPAL (*Pomona, CA, USA*)

Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral Mediated Tumor Growth. N.T. LU, N.M. LIU, J.Q. VU, D. PATEL, W. COHN, J. CAPRI, M. ZIEGLER, N. PATEL, A. TRAMONTANO, R. WILLIAMS, J. COX, J. WHITELEGGE, S.W. FRENCH (*Los Angeles, CA; Boston, MA, USA; London, UK*)

The Multiple Roles of Exosomes in Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (*Basel, Switzerland*)

Association of BIM Deletion Polymorphism and BIM- γ RNA Expression in NSCLC with EGFR Mutation. K. ISOBE, A. KAKIMOTO, T. MIKAMI, K. KABURAKI, H. KOBAYASHI, T. YOSHIZAWA, T. MAKINO, H. OTSUKA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, N. TOCHIGI, A. IYODA, S. HOMMA (*Tokyo, Japan*)

High Throughput Screening of Nutraceuticals for Evidence of Human Histone Deacetylase Inhibition and Analysis of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed Extract (*Vitis vinifera*) in HeLa cells. E.A. MAZZIO, K.F.A. SOLIMAN (*Tallahassee, FL, USA*)

A Comparative Study of the Molecular Characteristics of Familial Gliomas and Other Cancers. J. LU, M.G. BURNETT, M. SHPAK (*Austin, TX; Cambridge, MA, USA*)

The Impact of HRNPM and SLC1A5 in Pathogenesis and Prognosis in Epithelial Ovarian Cancer. K. BJERSAND, T. SEIDAL, I. SUNDSTRÖM POROMAA, H. ÅKERUD, I. SKIRNISDOTTIR (*Uppsala; Halmstad, Sweden*)

Characterization of Heparan Sulfate Proteoglycan-positive Recycling Endosomes Isolated from Glioma Cells. K.A. PODYMA-INOUE, T. MORIWAKI, A.R. RAJAPAKSHE, K. TERASAWA, M. HARA-YOKOYAMA (*Tokyo, Japan*)

Overexpression of HPV16 E6* Alters β -Integrin and Mitochondrial Dysfunction Pathways in Cervical Cancer Cells. W. EVANS, M. FILIPPOVA, V. FILIPPOV, S. BASHKIROVA, G. ZHANG, M.E. REEVES, P. DUERKSEN-HUGHES (*Loma Linda, CA, USA*)

Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients. S.F. STÄMPFLI, A. AKHMEDOV, S. HAUSLADEN, Z. VARGA, K.J. DEDES, J. HELLERMANN, T.F. LÜSCHER, G. KRISTIANSEN, F.C. TANNER, A. BREITENSTEIN (<i>Schlieren; Zurich; Schiers, Switzerland; Bonn, Germany</i>)	3259
An Alternative Surgery for an Atypical Kind of Grade C Postoperative Pancreatic Fistula Following Pancreaticoduodenectomy. E. VIRGILIO, M. LA TORRE, M. CAVALLINI (<i>Rome, Italy</i>)	3265
Urinary Tract Resections in Advanced-stage Cervical Cancer – A Series of Eight Cases. D.N. OPRESCU, N. BACALBASA, I. BALESCU, A. FILIPESCU (<i>Bucharest, Romania</i>)	3271
Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related? S. SACHANAS, G.A. PANGALIS, M. MOSCHOGIANNIS, X. YIAKOUMIS, E. KOULIERIS, P. TSIRKINIDIS, C. KALPADAKIS, D. RONTOGIANNI (<i>Athens; Heraklion, Greece</i>)	3277
Serum Levels of IGF-1 and IGFBP-3 in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas. D. KALFERT, M. LUDVIKOVA, O. TOPOLCAN, P. CELAKOVSKY, R. KUCERA, J. WINDRICHROVA, J. LUDVIK, K. SKALOVA, V. KULDA, M. PESTA, J. PLZAK (<i>Prague, Czech Republic</i>)	3281
Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly. S. JANSSEN, L. MANIG, S.E. SCHILD, D. RADES (<i>Lübeck, Germany; Scottsdale, AZ, USA</i>)	3287
Multiparametric MRI/TRUS Fusion Prostate Biopsy: Advantages of a Transperineal Approach. P. PEPE, A. GARUFI, G.D. PRIOLO, M. PENNISI (<i>Catania, Italy</i>)	3291
RT-PCR for Detecting ALK Translocations in Cytology Samples from Lung Cancer Patients. S. NAKAMICHI, M. SEIKE, A. MIYANAGA, M. CHIBA, K. MATSUDA, K. KOBAYASHI, A. TAKAHASHI, S. TAKEUCHI, Y. MINEGISHI, K. KUBOTA, A. GEMMA (<i>Tokyo, Japan</i>)	3295
Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma. T. KAWAI, M. KOCHI, M. FUJII, K. SONG, K. HAGIWARA, M. WATANABE, Y. MATSUNO, H. SUDA, R. YAGI, T. TAKAYAMA (<i>Tokyo, Japan</i>)	3301
Surgical Outcomes of Non-small Cell Lung Cancer in Patients with a History of Pancreaticobiliary Cancer. T. TAGAWA, K. ITO, K. FUKUZAWA, T. OKAMOTO, A. FUJINAGA, T. KAWASAKI, T. MASUDA, K. IWAKI, T. TERASHI, M. OKAMOTO, A. SHIROMIZU, A. MOTOHIRO, Y. MAEHARA (<i>Oita; Fukuoka, Japan</i>)	3307
JC Virus and Lung Adenocarcinoma: Fact or Myth? E. SINAGRA, D. RAIMONDO, E. GALLO, M. STELLA, M. COTTONE, F. ROSSI, M. MESSINA, M. SPADA, G. TOMASELLO, G. FERRARA, A.G. RIZZO (<i>Cefalu; Palermo, Italy</i>)	3311
Exhaled Breath Condensate Acidification Occurs During Surgery for Abdominal Cancer. A. MAHAIRIDOU, S. RODOPOULOU, I. TOMOS, E. MARATOU, E. MANALI, T. RAPTAKIS, S.A. PAPIRIS, A. KARAKATSANI (<i>Piraeus; Athens, Greece</i>)	3315
Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer. D. FURRER, S. JACOB, C. CARON, F. SANSCHAGRIN, L. PROVENCHER, C. DIORIO (<i>Quebec City, Canada</i>)	3323
ABSTRACTS OF THE JOINT INTERNATIONAL SYMPOSIA “VITAMIN D IN PREVENTION AND THERAPY” AND “BIOLOGIC EFFECTS OF LIGHT” 21-23 June, 2017 (<i>Homburg/Saar, Germany</i>)	3331

Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients. S. MUTO, H. TAKAGI, Y. OWADA, T. INOUE, Y. WATANABE, T. YAMAURA, M. FUKUHARA, N. OKABE, Y. MATSUMURA, T. HASEGAWA, J. OSUGI, M. HOSHINO, M. HIGUCHI, Y. SHIO, H. SUZUKI (<i>Fukushima, Japan</i>)	3169
Prognostic Significance of Preoperative Anemia in Patients Undergoing Surgery for Renal Cell Carcinoma: A Meta-analysis. L. XIA, G. HU, T.J. GUZZO (<i>Philadelphia, PA, USA; Shenyang, PR China</i>)	3175
Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin–Lipiodol Suspension for Hepatocellular Carcinoma. T. MATSUMOTO, H. ICHIKAWA, J. IMAI, T. HAYASHI, K. TOMITA, T. MINE, S. KOJIMA, N. WATANABE, T. HASEBE (<i>Hachioji, Japan</i>)	3183
Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC. M. MENCOBONI, R.A. FILIBERTI, P. TAVEGGIA, L. DEL CORSO, A. DEL CONTE, M.G. COVESNON, C. PUCCETTI, S. DONATI, L. AURIATI, D. AMOROSO, A. CAMERINI (<i>Genoa; Pordenone; Lido di Camaiore, Italy</i>)	3189
Antibiotic Use Does Not Appear to Influence Response to Nivolumab. C. KADERBHAI, C. RICHARD, J.D. FUMET, A. AARNINK, P. FOUCHER, B. COUDERT, L. FAVIER, A. LAGRANGE, E. LIMAGNE, R. BOIDOT, F. GHIRINGHELLI (<i>Dijon, France</i>)	3195
The Role of Concomitant Radiation Boost in Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. H. BADAKHSHI, M. ISMAIL, C. BOSKOS, K. ZHAO, D. KAUL (<i>Potsdam; Berlin, Germany; Athens, Greece; Shanghai, PR China</i>)	3201
Clinical Features and Outcome of Surgical Patients with Non-B Non-C Hepatocellular Carcinoma. S. WAKIYAMA, M. MATSUMOTO, K. HARUKI, T. GOCHO, T. SAKAMOTO, H. SHIBA, Y. FUTAGAWA, Y. ISHIDA, K. YANAGI (<i>Tokyo, Japan</i>)	3207
Duration of Preoperative Biliary Drainage as a Prognostic Factor After Pancreaticoduodenectomy for Pancreatic Head Cancer. M. MATSUMOTO, Y. NAKABAYASHI, Y. FUJIWARA, N. FUNAMIZU, R. NOAKI, S. ETO, H. SUGANO, M. OTSUKA, K. YANAGI (<i>Saitama; Tokyo, Japan</i>)	3215
Occupational Risk for Oral Cancer in Nordic Countries. L. TARVAINEN, J. SUOJANEN, P. KYRONEN, C. LINDQVIST, J.I. MARTINSEN, K. KJAERHEIM, E. LYNGE, P. SPAREN, L. TRYGGVADOTTIR, E. WEIDERPASS, E. PUKKALA (<i>Helsinki; Tampere, Finland; Oslo; Tromso, Norway; Copenhagen, Denmark; Stockholm, Sweden; Reykjavik, Iceland</i>)	3221
Effects of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma. Y. KITANO, Y.-I. YAMASHITA, K. YAMAMURA, K. ARIMA, T. KAIDA, T. MIYATA, S. NAKAGAWA, K. MIMA, K. IMAI, D. HASHIMOTO, A. CHIKAMOTO, H. BABA (<i>Kumamoto, Japan</i>)	3229
Changes in the Submandibular Gland in Patients with Head and Neck Cancer After Radiation Therapy: A Preliminary Study. Y. UCHIYAMA, S. KREIBORG, S. MURAKAMI, T. TSUJIMOTO, I. SUMIDA (<i>Osaka; Suita, Japan; Copenhagen, Denmark</i>)	3239
Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma. U. USLU, M. ERDMANN, S. SCHLIEP, J. DÖRRIE, N. SCHAFT, G. SCHULER, B. SCHULER-THURNER (<i>Erlangen, Germany</i>)	3243
<i>CTNNB1</i> Mutations in Ovarian Microcystic Stromal Tumors: Identification of a Novel Deletion Mutation and the Use of Pyrosequencing to Identify Reported Point Mutation. K. NA, E.K. KIM, W. JANG, H.-S. KIM (<i>Seoul, Republic of Korea</i>)	3249

Puzzling Results from BAP1 Germline Mutations Analysis in a Group of Asbestos-Exposed Patients in a High-risk Area of Northeast Italy. C. RIZZARDI, E. ATHANASAKIS, F. CAMMISULI, S. DAL MONEGO, Y.C.C. DE SPELORZI, F. COSTANTINIDES, F. GIUDICI, M. PINAMONTI, V. CANZONIERI, M. MELATO, L. PASCOLO (<i>Trieste; Aviano, Italy</i>)	3073
Palliative Radiotherapy in the Local Management of Stage IVB Esophageal Cancer: Factors Affecting Swallowing and Survival. G. SUZUKI, H. YAMAZAKI, N. AIBE, K. MASUI, K. TATEKAWA, N. SASAKI, T. KIMOTO, T. NISHIMURA, A. NAKASHIMA, T. TAKENAKA, H. FUJIWARA, T. ISHIKAWA, K. YAMADA (<i>Kyoto, Japan</i>)	3085
Rare Neoplasm Mimicking Neuoroendocrine Pancreatic Tumor: A Case Report of Solitary Fibrous Tumor with Review of the Literature. F.E. D'AMICO, C. RUFFOLO, M. ROMANO, M. DI DOMENICO, M. SBARAGLIA, A.P. DEI TOS, T. GAROFALO, A. GIORDANO, N. BASSI, M. MASSANI (<i>Padua; Treviso; Naples, Italy; Philadelphia, PA, USA</i>)	3093
CytoTrack Analysis Reveals Low Presence of Circulating Tumor Cells in the Perioperative Period in Patients with Non-metastatic Colorectal Cancer. M. GOGENUR, T. HILLIG, I. GOGENUR (<i>Koge; Hillerod, Denmark</i>)	3099
Complete Reversion of Familial Adenomatous Polyposis Phenotype Associated with Tacrolimus and Mycophenolate Mofetil Treatment Following Kidney Transplantation. V. PINSK, I. PINSK, G. LING, B. YERUSHALMI, L. OSYNTSOV, E. LING (<i>Beer Sheva, Israel</i>)	3105
Successful Treatment of Pituitary Germinoma with Etoposide, Cisplatin, Vincristine, Methotrexate and Bleomycin Chemotherapy Without Radiotherapy. A. SCHERZ, K. FELLER, S. BEREZOWSKA, V. GENITSCH, M. ZWEIFEL (<i>Bern, Switzerland</i>)	3111
Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. M. BANYS-PALUCHOWSKI, I. WITZEL, S. RIETHDORF, B. RACK, W. JANNI, P.A. FASCHING, E.-F. SOLOMAYER, B. AKTAS, S. KASIMIR-BAUER, K. PANTEL, T. FEHM, V. MÜLLER (<i>Hamburg; Munich; Ulm; Erlangen; Homburg/Saar; Essen; Düsseldorf, Germany</i>)	3117
Overexpression of EGFR as an Independent Prognostic Factor in Adenocarcinoma of the Esophagogastric Junction. K. ARATANI, S. KOMATSU, D. ICHIKAWA, T. OHASHI, M. MIYAMAE, W. OKAJIMA, T. IMAMURA, J. KIUCHI, K. NISHIBEPPU, T. KOSUGA, H. KONISHI, A. SHIOZAKI, H. FUJIWARA, K. OKAMOTO, H. TSUDA, E. OTSUJI (<i>Kyoto; Tokyo; Saitama, Japan</i>)	3129
Analysis of Factors for Predicting Survival in Soft-tissue Sarcoma with Metastatic Disease at Initial Presentation. T. NAKAMURA, H. KATAGIRI, Y. SHIDO, S. HAMADA, K. YAMADA, A. NAGANO, S. YAMADA, S. TSUKUSHI, D. ISHIMURA, A. MATSUMINE, A. SUDO, Y. NISHIDA (<i>Tsu; Nagaizumi; Hamamatsu; Nagoya; Okazaki; Gifu; Toyoake, Japan</i>)	3137
Assessments of Neoadjuvant Hormone Therapy Followed by Robotic-Assisted Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer. J.-C. HU, S.-C. HUNG, Y.-C. OU (<i>Taichung, Taiwan, ROC</i>)	3143
Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer. W. WANG, W. ZHONG, C. CHEN, Q. MENG, J. WEI (<i>Indianapolis, IN, USA; Shenyang; Dongguan, PR China; Inverness, UK</i>)	3151
Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer. M.Z. MUALLEM, A. PARASHKEVOVA, J. ALMUHEIMID, R. RICHTER, Y. DIAB, E.I. BRAICU, J. SEHOULI (<i>Berlin, Germany; Victoria, Australia</i>)	3157
Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen. S. KRUCK, J. HENNENLOTTER, B. AMEND, M. GEIGER, E. FILIPOVA, T. NEUMANN, V. STÜHLER, T. SCHUBERT, T. TODENHÖFER, S. RAUSCH, F. HUETTIG, A. STENZL, J. BEDKE (<i>Tuebingen, Germany</i>)	3163

with Taxane-based Adjuvant Chemotherapy. T. GAVRESSEA, K.T. KALOGERAS, G.-A. KOLIOU, F. ZAGOURI, G. LAZARIDIS, H. GOGAS, K. TSIGARIDAS, A. KOUTRAS, K. PETRAKI, C. MARKOPOULOS, E. PAZARLI, G. ARAVANTINOS, C. PAPADIMITRIOU, P. PAPAKOSTAS, N. KOUFOPOULOS, C. KARANIKIOTIS, S. CHRISAFI, H.P. KALOFONOS, D. PECTASIDES, G. FOUNTZILAS, K. PAVLAKIS (<i>Athens; Thessaloniki; Piraeus; Patras, Greece</i>)	2947
Enhancing 5-Fluorouracil Efficacy in a Primary Colorectal Cancer by Long-lasting Calcium Supplementation. K.-Y. JEONG, M. PARK, I.U. KIM, J.J. SIM, H.M. KIM (<i>Incheon, Republic of Korea</i>)	2959
Combination of Radiofrequency Ablation and Glycated Chitosan as Treatment on a Syngeneic Breast Tumor Model. H.-Y. CHIU, J.-D. LEU, C.-Y. CHANG, Y.-J. LEE, W.R. CHEN (<i>Taipei, Taiwan, ROC; Edmond, OK, USA</i>)	2965
Enhanced Susceptibility to 5-Fluorouracil in Human Colon Cancer Cells by Silencing of GRP78. S. YUN, Y.-S. HAN, J.H. LEE, S. KIM, S.H. LEE (<i>Baltimore, MD; Birmingham, AL, USA; Seoul; Asan, Republic of Korea</i>)	2975
Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells. N. YAMAGUCHI, M. OSAKI, K. ONUMA, T. YUMIOKA, H. IWAMOTO, T. SEJIMA, H. KUGOH, A. TAKENAKA, F. OKADA (<i>Tottori, Japan</i>)	2985
17-Allylaminio-17-demethoxygeldanamycin-induced Changes in [¹⁸ F]Fluorothymidine Uptake. H.J. LEE, D.H. KIM, S.J. LEE (<i>Seoul; Daejeon, Republic of Korea</i>)	2993
Modulation of Melanotransferrin and Transferrin Receptor 1 (TFRC)- and CD44-based Signaling for TFRC Up-regulation in Human Melanoma Cells. F. LAUBE, D. GLANZ (<i>Halle, Germany</i>)	3001
A Novel Near-infrared Fluorescent Protein, iRFP720, Facilitates Transcriptional Profiling of Prostate Cancer Bone Metastasis in Mice. M. HONDA, S. YOGOSAWA, M. KAMADA, Y. KAMATA, T. KIMURA, Y. KOIKE, T. HARADA, H. TAKAHASHI, S. EGAWA, K. YOSHIDA (<i>Tokyo, Japan</i>)	3009
vPARP Adjusts MVP Expression in Drug-resistant Cell Lines in Conjunction with MDR Proteins. K. WOJTOWICZ, R. JANUCHOWSKI, M. NOWICKI, M. ZABEL (<i>Poznan; Wroclaw, Poland</i>)	3015
Diversified β-2-adrenergic Receptor Expression and Action in Melanoma Cells. M.E. JANIK, D. SZŁĘZAK, M. SURMAN, A. GOŁAS, A. LITYŃSKA, M. PRZYBYŁO (<i>Kraków, Poland</i>)	3025
Clinical Studies	
Effect of Radiation Therapy on Survival in Hodgkin's Lymphoma: A SEER Data Analysis. S. MASTER, N. KOSHY, B. WILKINSON, L. ROSEN, G. MILLS, R. MANSOUR, R. SHI (<i>Shreveport, LA, USA</i>)	3035
Clinical Outcomes and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck. S. JANG, P.N. PATEL, R.J. KIMBLE, T.M. MCCULLOCH (<i>Madison, WI; Birmingham, AL, USA</i>)	3045
Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer. H. MIYATA, K. SUGIMURA, M. MOTOORI, Y. FUJIWARA, T. OMORI, Y. YANAGIMOTO, M. OHUE, M. YASUI, N. MIYOSHI, A. TOMOKUNI, H. AKITA, S. KOBAYASHI, H. TAKAHASHI, M. YANO (<i>Osaka, Japan</i>)	3053
Randomized Controlled Trial of Adjuvant Chemotherapy with Fluoropyrimidines Versus Surgery-alone for Gastric Cancer. J.H. MOON, Y. FUJIWARA, M. HIRAO, H. IMAMURA, Y. KIMURA, K. FUJITANI, J. FUJITA, S. TAMURA, S. TAKIGUCHI, M. YANO, M. MORI, Y. DOKI (<i>Osaka; Tottori; Hyogo, Japan</i>)	3061
Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity. S.L. NEUHAUSEN, H. SHANI, L.K. BOKER, L. STEELE, B.G. SILVERMAN, L. OTTINI, V. SILVESTRI, Y. LAITMAN, J. KORACH, T. PERRI, E. FRIEDMAN (<i>Duarte, CA, USA; Tel-Hashomer; Tel-Aviv, Israel; Rome, Italy</i>)	3069

MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. J. GONG, Y. CHEN, L. YANG, R. PILLAI, S. SHIRASAWA, M. FAKIH (<i>Duarte, CA, USA; Fukuoka, Japan</i>)	2831
Structure–Activity Relationship of Niclosamide Derivatives. Z. TANG, U.M. ACUÑA, N.F. FERNANDES, S. CHETTIAR, P.-K. LI, E.C. DE BLANCO (<i>Columbus, OH, USA</i>)	2839
Impact of Small Molecules on β -Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas. B. KRAMER, C. HOCK, J.D. SCHULTZ, A. LAMMERT, B. KUHLIN, R. BIRK, K. HÖRMANN, C. ADERHOLD (<i>Mannheim; Karlsruhe, Germany</i>)	2845
The Expression of BTS-2 Enhances Cell Growth and Invasiveness in Renal Cell Carcinoma. Q.T. PHAM, N. OUE, Y. YAMAMOTO, Y. SHIGEMATSU, Y. SEKINO, N. SAKAMOTO, K. SENTANI, N. URAOKA, M. TIWARI, W. YASUI (<i>Hiroshima, Japan; Houston, TX, USA; Chitwan, Nepal</i>)	2853
Protein Complex of Fibrinogen Gamma Chain and Complement Factor H in Ovarian Cancer Patient Plasma. K.-I. HONDA, R. ASADA, K. KAGEYAMA, T. FUKUDA, H. TERADA, T. YASUI, T. SUMI, M. KOYAMA, O. ISHIKO, T. SUGAWA (<i>Kashiwara; Sakai; Shobara; Osaka, Japan</i>)	2861
The Immunological Roles of Periostin/Tumor-Associated Macrophage Axis in Development of Dermatofibrosarcoma Protuberans. T. FUJIMURA, A. KAKIZAKI, Y. SATO, K. TANITA, S. FURUDATE, S. AIBA (<i>Sendai, Japan</i>)	2867
Immunoregulatory Function of Lymphatic Endothelial Cells in Tumor-draining Lymph Nodes of Human Gastric Cancer. M. TOKUMOTO, H. TANAKA, Y. TAUCHI, T. TAMURA, T. TOYOKAWA, K. KIMURA, K. MUGURUMA, M. YASHIRO, K. MAEDA, K. HIRAKAWA, M. OHIRA (<i>Osaka, Japan</i>)	2875
Intrahepatic HCV RNA Level and Genotype 1 Independently Associate with Hepatic Reticulon 3 Expression. C.-L. LIN, R.-N. CHIEN, K.-H. LIANG, P.-Y. KE, Y.-H. HUANG, C.-T. YEH (<i>Keelung; Taoyuan, Taiwan, ROC</i>)	2885
Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2. A. KUBAN-JANKOWSKA, M. GORSKA-PONIKOWSKA, M. WOZNIAK (<i>Gdansk, Poland</i>)	2893
The COOH-terminus of the IGF-1Ec Isoform Enhances the Proliferation and Migration of Human MCF-7 Breast Cancer Cells. P.F. CHRISTOPOULOS, E. PAPAGEORGIOU, C. PETRAKI, M. KOUTSILIERIS (<i>Athens, Greece</i>)	2899
Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice. R.M.G. DA COSTA, R. ARAÚJO, J.M.O. SANTOS, M. FERNANDES, T. NETO, H. SOUSA, J. RIBEIRO, M.M.S.M. BASTOS, P.A. OLIVEIRA, D. CARMO, F. CASACA, S. SILVA, C. LOPES, R. MEDEIROS (<i>Porto; Vila Real, Portugal</i>)	2913
Associating Liver Partition and Portal Vein Occlusion, Including Venous Congestion, Induction in Rats. D. KAWAGUCHI, Y. HIROSHIMA, Y. KIKUCHI, K. MATSUO, K. TANAKA (<i>Chiba, Japan</i>)	2919
Expression and Prognostic Significance of <i>EP300</i> , <i>TP53</i> and <i>BAX</i> in Clear Cell Renal Cell Carcinoma. J. GODLEWSKI, B.E. KRAZINSKI, A.E. KOWALCZYK, J. KIEWISZ, J. KIEZUN, P. KWIATKOWSKI, A. SLIWIŃSKA-JEWSIEWICKA, P.W. WIERZBICKI, Z. KMIEĆ (<i>Olsztyn; Gdansk, Poland</i>)	2927
Aberration of <i>p73</i> Promoter Methylation in Chondrosarcoma. P. LIU, C. GARBUZZ, F.J. HORNICEK, F. LIU, Z. DUAN (<i>Boston, MA, USA; Henan, PR China</i>)	2939
The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated	